Key terms
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALPN news
Yesterday
2:05pm ET
Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
Apr 12
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Apr 11
7:55pm ET
Maintaining Hold Rating Amid Vertex Pharmaceuticals’ Acquisition of Alpine Immune Sciences
Apr 11
7:48pm ET
Alpine Immune Sciences downgraded to Market Perform from Outperform at Leerink
Apr 11
10:49am ET
Analyst thinks this drugmaker could be next after Alpine’s $4.9B acquisition
Apr 11
9:40am ET
DoorDash upgraded, Airbnb downgraded: Wall Street’s top analyst calls
Apr 11
8:10am ET
Wedbush downgrades Alpine Immune, sees takeout deal closing
Apr 11
7:27am ET
Alpine Immune Sciences downgraded to Neutral from Buy at H.C. Wainwright
Apr 11
7:22am ET
Alpine Immune Sciences downgraded to Peer Perform at Wolfe Research
Apr 11
6:46am ET
Alpine Immune Sciences downgraded to Neutral from Outperform at Wedbush
Apr 11
6:34am ET
Evercore expects Vera Therapeutics to trade up on Alpine acquisition news
Apr 11
6:26am ET
Vertex Pharmaceuticals upgraded to Outperform from In Line at Evercore ISI
Apr 11
5:10am ET
Alpine Immune downgraded to Sector Perform from Outperform at RBC Capital
Apr 11
12:12am ET
Alpine Immune Sciences downgraded to Equal Weight at Morgan Stanley
Apr 10
4:30pm ET
Alpine Immune Sciences trading resumes
Apr 10
4:17pm ET
Alpine Immune Sciences share updated clinical data for povetacicept in IgAN
Apr 10
4:09pm ET
Alpine Immune Sciences to resume trading at 4:30 pm ET
Apr 10
4:02pm ET
Vertex to acquire Alpine Immune Sciences for $65 per share
Apr 10
4:00pm ET
Alpine Immune Sciences trading halted, news pending
Apr 10
12:41pm ET
Alpine Immune trading resumes, shares up 14% after Bloomberg report
Apr 10
12:39pm ET
Alpine Immune weighing sale after takeover interest, Bloomberg says
Apr 10
12:38pm ET
Alpine Immune Sciences trading resumes
Apr 10
12:36pm ET
Alpine Immune jumps 7% to $41.74 after Bloomberg report of takeover interest
Apr 10
12:36pm ET
Alpine Immune weighing sale after attracting interest, Bloomberg reports
Apr 10
12:33pm ET
Alpine Immune Sciences trading halted, volatility trading pause
Apr 08
3:26am ET
Buy Rating Affirmed for Alpine Immune Sciences Amid Positive Clinical Trial Results
Apr 05
4:43pm ET
Alpine Immune Sciences Announces New Chief Accounting Officer
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
8:36am ET
Vera Therapeutics price target raised to $34 from $21 at Wedbush
Mar 21
2:16am ET
Buy Rating Affirmed for Alpine Immune Sciences Amid Positive Povetacicept Trials and Strong Clinical Outlook
Mar 21
2:02am ET
Alpine Immune Sciences’ Growth at Risk: Navigating FDA and SEC Disruptions Amidst Political and Health Uncertainties
ALPN Financials
Key terms
Ad Feedback
ALPN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALPN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
